FDA approval of obesity medicine by Eli Lilly could shake up the weight reduction industry. Eli Lilly is to apply for approval of an obesity therapy that, according to a late-stage trial, can reduce a person’s body weight by almost a sixth. This has raised hopes for a new blockbuster treatment that can combat the epidemic of obesity that is occurring all over the world.
People who have type 2 diabetes and are overweight or obese were able to lose an average of about 16 percent of their body weight, which is equivalent to 15.6 kilograms, over almost 17 months when they took a high dose of the medicine Tirzepatide, which was manufactured in the United States.
Read more: Elon Musk Spills the Beans on Tesla’s Future.
It was given the green light by the Food and Drug Administration in the United States in May of last year to treat type-2 diabetes under the brand name Mounjaro. However, Lilly hopes to acquire the green light to market the drug to treat obesity to capitalize on the rapidly expanding market for weight loss treatments.
Patient demand and investor interest in the sector are being driven by a new class of obesity and diabetes medications that, in some situations, can generate weight loss comparable to that achieved through bariatric surgery. The demand for the treatments has been bolstered due to endorsements made on social media by Hollywood stars and celebrities such as Elon Musk.
It was announced on Thursday that Lilly had increased its earnings predictions for 2023 due to the strong demand for the diabetic treatment Mounjaro. This highlights the potential of Mounjaro as a competitor to the obesity drug Wegovy, which Novo Nordisk manufactures.
Tirzepatide has the potential to become the drug that has sold the most units throughout the history of medicine, according to analysts, who predict that its annual peak sales might reach as high as $50 billion if it is given the go-ahead to treat obesity, which is anticipated to happen by the end of this year.
Evan Seigerman, an analyst at BMO Capital Markets, stated that the findings of the trials demonstrated that the “wait is over” and that Mounjaro was on the path to receiving regulatory clearance and potentially reaching peak sales of more than $50 billion across all indications.
“These data reinforce our view that Mounjaro is the best injectable option for weight loss, besting Novo’s Wegovy,” he continued. “Mounjaro beats Wegovy by a wide margin.” Given Lilly’s investment in manufacturing, we anticipate a rapid product uptake once it is approved.
Following the publication of Lilly’s financial and trial results, the company’s stock price increased by more than 3 percent in the pre-market trading session.
According to data published by the Centres for Disease Control and Prevention, two out of every five people in the United States suffer from obesity. As a result, pharmaceutical companies are working feverishly to produce a new generation of pharmaceuticals to combat a rising epidemic in the country.
World Health Organisation (WHO) estimates that over 650 million individuals worldwide suffer from obesity. Tirzepatide, manufactured by Lilly, is given as an injection once a week, reducing a person’s appetite while increasing the amount of energy the person expends.
Obesity medicine manufacturers Lilly and Novo Nordisk still face an uphill battle to win funding from both public and private insurers for their products. They claim that obesity generates issues that can lead to more expensive medical care in the future, but due to the size of the market, they may meet resistance from insurers.
Lilly stated that it hoped to finish its application for approval of Tirzepatide for obesity in the following weeks and anticipated a decision from the FDA as early as late 2023.
